News stories about Marrone Bio Innovations (NASDAQ:MBII) have been trending positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Marrone Bio Innovations earned a news impact score of 0.28 on Accern’s scale. Accern also gave news headlines about the basic materials company an impact score of 46.9296084022038 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Why Marrone Bio shares rose 22 percent Friday (bizjournals.com)
- Is Marrone Bio Innovations (MBII) Stock a Solid Choice Right Now? (finance.yahoo.com)
- Research Analysts Set Expectations for Marrone Bio Innovations Inc’s FY2018 Earnings (MBII) (americanbankingnews.com)
- Marrone Bio Innovations Inc Forecasted to Post Q1 2018 Earnings of ($0.04) Per Share (MBII) (americanbankingnews.com)
- BRIEF-Marrone Bio Innovations Inc Files For Non-Timely 10-K With U.S. SEC (reuters.com)
MBII stock opened at $3.25 on Monday. The stock has a market capitalization of $331.80, a PE ratio of -3.04 and a beta of -0.57. The company has a debt-to-equity ratio of -1.23, a current ratio of 0.87 and a quick ratio of 0.42. Marrone Bio Innovations has a 12 month low of $0.85 and a 12 month high of $3.39.
A number of equities research analysts have issued reports on the stock. ValuEngine upgraded shares of Marrone Bio Innovations from a “strong sell” rating to a “sell” rating in a research note on Saturday. Jefferies Group reiterated a “hold” rating and set a $1.55 price objective on shares of Marrone Bio Innovations in a research note on Wednesday, March 21st. Zacks Investment Research downgraded shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a research note on Thursday, February 15th. Finally, HC Wainwright set a $4.00 price objective on shares of Marrone Bio Innovations and gave the stock a “buy” rating in a research note on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $2.18.
In related news, insider Ardsley Advisory Partners bought 6,666,667 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was purchased at an average price of $0.75 per share, with a total value of $5,000,000.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.80% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Marrone Bio Innovations (MBII) Earning Favorable News Coverage, Analysis Finds” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3343250/marrone-bio-innovations-mbii-earning-favorable-news-coverage-analysis-finds.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.